Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekten av Qualia Glutathione+ på blodets glutathionnivåer

1. oktober 2026 oppdatert av: Qualia Life Sciences

Effekten av Qualia Glutathione+ på blodglutathionnivåer

This is a double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be assigned to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Studieoversikt

Detaljert beskrivelse

Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. No other aspect of the study design, conduct, or analysis changed.

Studietype

Intervensjonell

Registrering (Faktiske)

56

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Carlsbad, California, Forente stater, 92011
        • Qualia Life Sciences

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

45 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion criteria:

  • Provide voluntary, written, informed consent to participate in the study
  • Agree to provide a valid cell phone number and are willing to receive communications through text
  • Can read and write English
  • Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
  • Willing to complete questionnaires, records, and diaries associated with the study.
  • Healthy male and female participants aged 45-75 years
  • Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20)
  • Willing to avoid starting new or stopping any existing dietary supplements throughout the study

Exclusion criteria:

  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
  • Known food intolerances/allergy to any ingredients in the product
  • Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
  • Having had a significant cardiovascular event in the past 6 months
  • Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
  • On immunosuppressive therapy
  • Adults lacking capacity to consent
  • Active Smokers
  • Diagnosed Diabetics

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Qualia Glutathione+ version 1

Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences

Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences

Aktiv komparator: Qualia Glutathione+ version 2

Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences

Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences

Placebo komparator: Placebo

Rice flour placebo

Rice flour

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total Glutathione levels from baseline to Day 20
Tidsramme: 0-20 days

To assess between-group differences in the change in blood Total Glutathione levels from baseline to Day 20 following supplementation with Qualia Glutathione version 1 versus placebo and Qualia Glutathione version 2 versus placebo

0-20 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
between-group differences in blood Total Glutathione levels
Tidsramme: baseline to day 20

To assess the between-group differences in blood Total Glutathione levels from baseline to Day 20 following supplementation between Qualia Glutathione version 1 and Qualia Glutathione version 2.

baseline to day 20
within-group differences in the change in blood Glutathione levels
Tidsramme: baseline to day 20

To assess within-group differences in the change in blood Glutathione levels

baseline to day 20
Safety and Tolerability survey
Tidsramme: baseline to days 7, 14 and 20

To evaluate side effect profiles using a custom Safety and Tolerability survey.

baseline to days 7, 14 and 20
PROMIS Global Health-10
Tidsramme: baseline to days 7, 14 and 20

The PROMIS® Global Health Scale v1.2 (also known as the PROMIS-GH or PROMIS-10) is a 10-item, non-disease-specific questionnaire for adults to assess general physical and mental health. It yields two main scores, a Global Physical Health (GPH) T-score and a Global Mental Health (GMH) T-score, derived from four items each, to understand overall health perceptions. The scale is widely translated and free for use in clinical and research settings.

  • Raw Score Minimum and Maximum: 0-20
  • The higher the score, the better
baseline to days 7, 14 and 20
PROMIS Short Form v1.0 - Fatigue 10a
Tidsramme: baseline to days 7, 14 and 20

The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal rather than disease-specific. All assess fatigue over the past seven days.

Raw Score Minimum and Maximum: 10-50 the lower the better

baseline to days 7, 14 and 20
PROMIS Cognitive Function - Short Form 8a
Tidsramme: baseline to days 7, 14 and 20

The PROMIS Cognitive Function v2.0 - Short Form 8a is an 8-item self-report questionnaire designed to assess perceived cognitive function over the past seven days. It measures difficulties in areas such as forming thoughts, concentration, attention, thinking speed, memory, and the ability to shift between tasks.

- Raw Score Minimum and Maximum: 8-40 - The higher the score, the better

baseline to days 7, 14 and 20

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. november 2025

Primær fullføring (Faktiske)

22. desember 2025

Studiet fullført (Faktiske)

8. januar 2026

Datoer for studieregistrering

Først innsendt

24. oktober 2025

Først innsendt som oppfylte QC-kriteriene

24. oktober 2025

Først lagt ut (Faktiske)

29. oktober 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • QLS-019

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere